Home » Health Canada Allows Acasti Pharma to Initiate CaPre Phase II Trial
Health Canada Allows Acasti Pharma to Initiate CaPre Phase II Trial
Health Canada has approved Acasti Pharma’s clinical trial application (CTA) to commence a Phase II trial of CaPre. Following the approval, the company expects to start a double blind, placebo controlled and randomized Phase II trial to assess the usage of CaPre for the treatment of patients with dyslipidemia.
PBR
PBR
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May